Skip to content
Screener

Rapport Therapeutics, Inc. RAPP Q2 2026 earnings

Reported August 5, 2026 · Before market open

Revenue-
EPS-$1.19Miss by $0.07
EPS estimate-$1.12

Next report

Nov 5, 2026 (in 3 months)
EPS estimate-$1.21

Financials

Q2 2026

Income statement

See full
Revenue-—
Operating income-$60.8M-106%
Net income-$56.6M-112%
EPS (diluted)-$1.19-58.7%

Balance sheet

See full
Cash & equivalents$63.6M+15.5%
Total debt$10.1M-14.8%
Total equity$422.9M+60.5%
Total assets$459.0M+60.8%

Cash flow

See full
Operating cash flow-$41.5M-65.4%
CapEx$78.0K+255%
Free cash flow-$41.5M-65.5%

Valuation & ratios

Valuation

as of 08/07/26
See full
Market cap$2.22B+317%
Enterprise value$2.17B+343%
P/S111.2×—

Returns & leverage

See full
Return on equity-40%+22.3pp
Debt / equity0×0.0×
Current ratio15.7×-7.0×

FAQ

When did Rapport Therapeutics, Inc. report Q2 2026 earnings?
Rapport Therapeutics, Inc. (RAPP) reported Q2 2026 earnings on August 5, 2026 before market open.
What were Rapport Therapeutics, Inc.'s Q2 2026 revenue and EPS?
Rapport Therapeutics, Inc. reported revenue of - and eps of $-1.19 for Q2 2026.
Did Rapport Therapeutics, Inc. beat estimates in Q2 2026?
EPS missed the consensus estimate of $-1.12 by $0.07.
How did Rapport Therapeutics, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 58.7% from $-0.75.
Where can I find Rapport Therapeutics, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-333853) and the 10-Q periodic report (0001193125-26-333862) directly on SEC EDGAR. The filing index links above go to sec.gov.